Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-05
2008-11-25
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S153000, C546S157000, C546S162000, C546S176000, C546S177000, C514S312000, C514S313000, C514S314000, C514S228200, C514S235200, C514S253060, C544S062000, C544S128000, C544S363000
Reexamination Certificate
active
07456196
ABSTRACT:
Compounds of formula (I)are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
REFERENCES:
patent: 1860286 (1932-05-01), Hartman et al.
patent: 3489756 (1970-01-01), Bolhofer et al.
patent: 3639476 (1972-02-01), Eberle et al.
patent: 4327022 (1982-04-01), Bailey
patent: 5480883 (1996-01-01), Spada et al.
patent: 6002008 (1999-12-01), Wissner et al.
patent: 6225328 (2001-05-01), Bernardon
patent: 6300352 (2001-10-01), Cheshire et al.
patent: 6358515 (2002-03-01), Ogata et al.
patent: 149 007 (1931-11-01), None
patent: 556 324 (1932-08-01), None
patent: 1 122 756 (1968-08-01), None
patent: 1178400 (1970-01-01), None
patent: 94/17079 (1994-08-01), None
patent: 95/01426 (1995-01-01), None
patent: 95/09159 (1995-04-01), None
patent: 98/38156 (1998-09-01), None
patent: 98/57931 (1998-12-01), None
patent: 00/06254 (2000-02-01), None
patent: WO 2000018761 (2000-04-01), None
patent: 00/27815 (2000-05-01), None
patent: 02/074758 (2002-09-01), None
patent: 03/093237 (2003-11-01), None
Blier et al. (Biol. Psychiatry 2003; 53: 193-203).
Airaksinen et al., “Histamine Neurons in Human Hypothalamus: Anatomy in Normal and Alzeimer Diseased Brains,” Neuroscience 44(2):465-481 (1991).
Andrés et al., “A Simple Steroselective Synthesis Of Enantiopure 2-Substituted Pyrrolidines and Piperidines From Chiral (R)-Phenylglycinol-Derived Bicyclic 1,3-Oxazolidines,” Eur. J. Org. Chem. 1719-1726 (2000).
Aranyos et al., “Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,” J. Am Chem. Soc. 121:4369-4378 (1999).
Azzolina et al. “Chemical and Biological Profileof Racemic and Optically Active Dialkylaminoalkylnaphtalenes with Analgesic Activity” Tetrahedron Asymmetry, vol. 13, (2002) pp. 1073-1081.
Bachman et al., “Quinoline Derivatives from 2- and 4-Chloroquinolines,” Journal of Organic Chemistry, American Chemical Society. Easton, US 9:302-309 (1944).
Baston et al., “A New Route To 6-Aryl-Substituted 3,4-Dihydronaphthalene Derivates Via Pd (O)-Catalyzed Cross-Coupling Reaction of Aryl Zinc Chlorides With an Aryl Triflate,” Synthetic Communication 28(14):2725-2729 (1998).
Bjenning et al., “Peripherally Administered Ciproxifan Elevates Hypothalamic Histamine Levels And Potently Reduces Food Intake in the Sprague Dawley Rat,” Histamine Research In The New Mellennium, Proceedings Of The International Sendai Histamine Symposium Held In Sendai, Japan, Nov. 22-25, 2000, p. 449-450.
Coutts et al., “Calmodulin Antagonists as Potential Antifungal Agents,” Pesticide Science, Elsevier Applied Science Publisher. Barking, GB 51(1):99-101 (1997).
Dai et al., “The First General Method For Palladium-Catalyzed Negishi Cross-Coupling Of Aryl And Vinyl Chlorides: Use of Commercially Available Pd(P(t-Bu)3)2as a Catalyst,” J. Am. Chem Soc. 123:2719-2724 (2001).
De Almeida et al., “Memory Facilitation by Histamine,” Arch. Int. Pharmacodyn., 283:193-198 (1986).
Delaunois et al., “Modulation Of Acetylcholine, Capsaicin and Substance P Effects by Histamine H3Receptors in Isolated Perfused Rabbit Lungs,” European Journal Of Pharmacology, 277:243-250 (1995).
Dimitriadou et al., “Functional Relationship Between Mast Cells and C-Sensitive Nerve Fibres Evidenced by Histamine H3-Receptor Modulation in Rat Lung and Spleen,” Clinical Science, 87:151-163 (1994).
Dohle et al., “Copper-Mediated Cross-Coupling of Functionalized Arylmagnesium Reagents with Functionalized Alkyl and Benzylic Halides,” Organic Letters 3(18):2871-2873 (2001).
Duméry et al., “Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat,” Exp. Brain. Res., 67:61-69 (1987).
Ellingboe et al., “Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole 2-Oxides,” J. Med. Chem. 36:2485-2493 (1993).
Elworthy et al., “The Configurational Stability of Chiral Lithio α-Amino Carbanions. The Effect of Li-O vs. Li-N Complexation,” Tetrahedron 50(20):6089-6096 (1994).
Fitzsimons et al., “Histamine Receptors Signalling in Epidermal Tumor Cell Lines With H-rasGene Alterations,” Inflamm. Res., 47, Supplement 1, S50-S51 (1998).
Fox et al., “Effects of Histamine H3Receptor Ligands GT-2331 And Ciproxifan in a Repeated Acquisition Response in the Spontaneously Hypertensive Rat Pup,” Behavioural Brain Research 131:151-161 (2002).
Gaffield et al., “Chiroptical Properties of N-Nitrosopyrrolidines and N-Nitrosamino Acids,” Tetrahedron 37:1861-1869 (1981).
Haas et al., Subcortical Modulation of Synaptic Plasticity in the Hippocampus, Behavioural Brain Research, 66:41-44 (1995).
Hartwig, “Transition Metal Catalyzed Synthesis of Arylamines and Aryl Ethers From Aryl Halides and Triflates: Scope And Mechanism,” Angew. Chem. Int. Ed. 37:2046-2067 (1998).
Hatta et al., “Activation of Histamine H3Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia1,2,” The Journal Of Pharmacology And Experimental Therapeutics, 283(2):494-500 (1997).
Imamura et al., “Activation Of Histamine H3-Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia,” Circulation Research, 78(3):475-481 (1996).
Imamura et al., “Histamine H3-Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C fibers,” Circulation Research, 78(5):863-869 (1996).
Imamura et al., “Histamine H3-Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers,” Circulation Research, 78(5):863-869 (1996).
Itoh et al., “Thioperamide, A Histamine H3Receptor Antagonist, Powerfully Suppresses Peptide YY-Induced Food Intake In Rats,” Biol. Psychiatry 45:475-481 (1999).
Kamei et al., “Influence Of Certain H1-Blockers On The Step-Through Active Avoidance Response In Rats,” Psychopharmacology, 102:312-318 (1990).
Kamei et al., “Participation Of Histamine In The Step-Through Active Avoidance Response And Its Inhibition By H1-Blockers,” Japan J. Pharmacol., 57:473-482 (1991).
Kiyomori et al., “An Efficient Copper-Catalyzed Coupling Of Aryl Halides With Imidazoles,” Tetrahedron Letters 40:2657-2660 (1999).
Klapars et al., “A General And Efficient Copper Catalyst For The Amidation of Aryl Halides And TheN-Arylation Of Nitrogen Heterocycles,” J. Am. Chem. Soc. 123:7727-7729 (2001).
Kwong et al., “Copper-Catalyzed Coupling Of Alkylamines And Aryl Iodides: An Efficient System Even In An Air Atmosphere,” Organic Letters 4(4):581-584 (2002).
Leurs et al., “The Histamine H3-Receptor: A Target For Developing New Drugs,” Progress In Drug Research, 39:127-165 (1992).
Leurs et al., “The Medicinal Chemistry And Therapeutic Potentials Of Ligands Of The Histamine H3Receptor,” Progress In Drug Research, 45:107-165 (1995).
Leurs et al., “Therapeutic Potential Of Histamine H3Receptor Agonists And Antagonists,” Trends In Pharm. Sci, 19:177-183 (1998).
Levi et al., “Histamine H3-Receptors: A New Frontier In Myocardial Ischemia,” The Journal Of Pharmacology And Experimental Therapeutics, 292(3):825-830 (2000).
Li et al., “Highly Active, Air-Stable Versatile Palladium Catalysts For The C-C, C-N, And C-S Bond Formations Via Cross-Coupling Reactions Of Aryl Chlorides,” J. Org. Chem. 66:8677-8681 (2001).
Li et al., “The First Phosphine Oxide Ligand Precursors For Transition Metal Catalyzed Cross-Coupling Reactions: C-C, C-N, And C-S Bond Formation On Unactivated Aryl
Altenbach Robert J.
Cowart Marlon D.
Liu Huaqing
Abbott Laboratories
Chen Portia
Habte Kahsay T
LandOfFree
Bicyclic-substituted amines as histamine-3 receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic-substituted amines as histamine-3 receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic-substituted amines as histamine-3 receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034439